[ X
]
|
Annual
Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934 [Fee Required]
For the
Fiscal Year Ended December 31, 2020
|
[
]
|
Transition
Report Under Section 13 or 15(d) of the Securities Exchange Act of
1934 [No Fee Required]
|
TEXAS
|
|
75-1974352
|
(State
or other jurisdiction of incorporation or
organization)
|
|
(IRS
Employer Identification No.)
|
|
|
|
4134 Business Park Drive, Amarillo, Texas
|
|
79110-4225
|
(Address
of principal executive offices)
|
|
Zip
Code
|
Large accelerated filer [ ]
|
|
Accelerated filer [ ]
|
Non-accelerated filer [ ]
|
|
Smaller reporting company [√]
|
Emerging growth company [ ]
|
|
|
●
|
Preclinical
laboratory and animal tests;
|
●
|
Submission
of an investigational new drug application, or IND, which must
become effective before human clinical trials may
begin;
|
●
|
Adequate
and well-controlled human clinical trials to establish the safety
and efficacy of the proposed drug for its intended
use;
|
●
|
Pre-approval
inspection of manufacturing facilities and selected clinical
investigators;
|
●
|
Submission
of a New Drug Application (NDA) to the FDA; and
|
●
|
FDA
approval of an NDA, or of an NDA supplement (for subsequent
indications or other modifications, including a change in location
of the manufacturing facility).
|
Stock Plans
1
|
|
Issue Date
Range
|
Total Options
Authorized
|
Options
Issued
|
Options
Remaining
|
Amarillo
Biosciences, Inc., 2018 Employee Stock Option Plan2,
3
|
|
9/26/18 –
9/26/28
|
6,000,000
|
850,000
|
5,150,000
|
Amarillo
Biosciences, Inc., 2018 Officers, Directors, Employees, and
Consultants Nonqualified Stock Option Plan2
|
|
9/26/18 –
9/26/28
|
20,000,000
|
3,807,000
|
16,193,000
|
Date
|
Number of
Options 1Qualified*
|
Number of
Options Nonqualified
|
Weighted Average
Exercise Price
|
Weighted Average
Remaining Contractual Term
|
Aggregate
Intrinsic Value
|
Balance December
31, 2018
|
950,000
|
3,995,000
|
$0.38
|
9
years -
|
-
|
Exercised
|
-
|
-
|
-
|
-
|
-
|
Expired or
Forfeited
|
100,000
|
188,000
|
$0.38
|
-
|
-
|
Balance December
31, 2019
|
850,000
|
3,807,000
|
$0.38
|
8
years -
|
-
|
Granted
2020
|
-
|
-
|
-
|
-
|
|
Exercised
|
-
|
-
|
-
|
-
|
-
|
Expired or
Forfeited
|
|
|
$0.38
|
-
|
-
|
Balance December
31, 2020
|
850,000
|
3,807,000
|
$0.38
|
7
years -
|
|
Vested as of
December 31, 2020
|
390,000
|
1,522,800
|
$0.38
|
7
years -
|
|
Note
#.
|
Conversion
Rate
|
Interest
Rate3
|
December 31,
2020
Principal
Amount4
|
December 31,
2019
Principal
Amount
|
Note 1 -
Chen
|
$0.1680
|
0.75%
|
$114,026
|
$114,026
|
Note 2 -
Chen
|
$0.1875
|
0.65%
|
$262,500
|
$262,500
|
Note 3.19 -
Chen
|
$0.2500
|
1.85%
|
$39,620
|
$39,620
|
Note 4.19 -
Chen
|
$0.2500
|
1.61%
|
$14,879
|
$12,435
|
Note 5.19 –
i2China
|
$0.2500
|
1.85%
|
$16,000
|
$16,000
|
Note 6.20 -
Chen
|
$0.2500
|
1.85%
|
$216,600
|
$-
|
Note 7.20 -
Chen
|
$0.2500
|
1.60%
|
$23,366
|
$-
|
Note 8.20a –
i2China5
|
$0.2500
|
1.85%
|
$48,000
|
$-
|
Note 8.20b –
i2China6
|
$0.2500
|
1.85%
|
$84,000
|
$-
|
Note 9.21 -
Chen7
|
N/A
|
0.13%
|
$134,010
|
$-
|
Total
Convertible Notes – Related Party
|
$953,001
|
$444,581
|
Office
Received
|
|
Date
Received
|
Amount
US
|
U.S.
|
|
4/13/2020
|
$10,000
|
U.S.
|
|
7/27/2020
|
$50,000
|
U.S.
|
|
8/10/2020
|
$25,000
|
U.S.
|
|
11/2/2020
|
$15,000
|
Taiwan8
|
|
11/5/2020
|
$14,010
|
U.S.
|
|
12/15/2020
|
$10,000
|
U.S.
|
|
12/22/2020
|
$10,000
|
|
|
Total
|
$134,010
|
Name
|
|
Age
|
|
Position
|
Stephen
T. Chen, Ph.D.
|
|
71
|
|
Chairman
of the Board, Chief Executive Officer President, Chief Financial
Officer, Chief Operating Officer and Director
|
Bernard
Cohen
|
|
67
|
|
Vice
President - Administration
|
Yasushi
Chikagami
|
|
81
|
|
Director
|
Daniel
Fisher .
|
|
76
|
|
Director
|
Nicholas
Moren .
|
|
74
|
|
Director
|
Beatrice
Liu, Ph.D., CPA
|
|
56
|
|
Director
|
Name and
Principal Position
|
Number of Late
Reports
|
Known Failures
to File a Required Form
|
Dr. Stephen T.
Chen, Chairman of the Board, Chief Executive Officer, President,
and Chief Financial Officer
|
0
|
0
|
Bernard Cohen, Vice
President – Administration
|
0
|
0
|
Yasushi Chikagami,
Director
|
0
|
0
|
Daniel Fisher,
Director
|
0
|
0
|
Nicholas Moren,
Director
|
0
|
0
|
Edward L. Morris,
Director
|
0
|
0
|
Dr. Beatrice Liu,
Director
|
0
|
0
|
Summary
Compensation Table
|
||||||
|
|
|
Annual
Compensation
|
Long Term
Compensation
|
||
Name and
Principal Position
|
|
Year
|
Salary
|
Bonus
|
Other
Compensation
|
Securities
Underlying Options
|
Dr. Stephen T.
Chen,
Chairman
of the Board,
President,
Chief
Executive
Officer, and Chief Financial Officer
|
|
2020
|
$240,975
|
$-
|
$100,000
|
-
|
|
|
2019
|
$249,633
|
$-
|
$100,000
|
-
|
|
|
2018
|
$240,000
|
$-
|
$100,000
|
-
|
Mr. Bernard
Cohen,
Vice
President – Administration.
|
|
2020
|
$71,085
|
$-
|
$12,000
|
-
|
|
|
2019
|
$71,398
|
$-
|
$12,000
|
-
|
|
|
2018
|
$70,000
|
$12,500
|
$12,000
|
-
|
Name and
Address
|
Amount and
Nature of Beneficial Ownership
|
Percent of Class
Owned9
|
Stephen T. Chen,
Ph.D.
4134 Business Park
Drive
Amarillo, Texas
79110
|
12,505,477
|
24.62%
|
Hung Lan Lee4134
Business Park Drive
Amarillo, Texas
79110
|
4,000,000
|
7.88%
|
ANXON International
Inc.4134 Business Park Drive
Amarillo, Texas
79110
|
2,459,153
|
4.84%
|
Name and Address
of Owner
|
Amount and
Nature of Beneficial Ownership
|
Percent of Class
Owned10
|
Stephen T. Chen,
Ph.D.4134 Business Park Drive
Amarillo, Texas
79110
|
12,505,47711
|
24.62%
|
Bernard
Cohen
4134 Business Park
Drive
Amarillo, Texas
79110
|
236,362
|
0.47%
|
Yasushi
Chikagami
4134 Business Park
Drive
Amarillo, Texas
79110
|
2,647,153
|
5.21%
|
Daniel
Fisher
4134 Business Park
Drive
Amarillo, Texas
79110
|
150,400
|
0.30%
|
Nicholas
Moren
4134 Business Park
Drive
Amarillo, Texas
79110
|
150,400
|
0.30%
|
Beatrice Liu,
Ph.D., CPA (ROC & U.S.)
4134 Business Park
Drive
Amarillo, Texas
79110. 104
|
-
|
-
|
Total Group (all
directors and executive officers – 5 persons)
|
15,689,792
|
30.90
|
|
2020
|
2019
|
PWR
CPA
|
$35,000
|
$18,500
|
LBB &
Associates Ltd., LLP
|
$-
|
$20,750
|
Report of Independent Registered Public Accounting
Firm
|
F-1
|
Consolidated Balance Sheets as of December 31, 2020 and
2019
|
F-2
|
Consolidated Statements of Operations for the years ended December
31, 2020 and 2019
|
F-3
|
Statements of Stockholders’ Equity (Deficit) for the years
ended December 31, 2020 and 2019
|
F-4
|
Statements of Cash Flows for the years ended December 31, 2020 and
2019
|
F-5
|
Notes to Financial Statements for the years ended December 31, 2020
and 2019
|
F-6
|
|
INCORPORATED BY REFERENCE
|
||||
EXHIBIT NUMBER
|
DESCRIPTION
|
FILED WITH THIS FORM 10-K
|
FILING DATE WITH SEC
|
FORM
|
EXH #
|
|
|
|
|
|
|
Restated
Certificate of Formation of the Company, dated and filed July 27,
2015
|
|
3/30/2016
|
10-K
|
3.i.
|
|
Bylaws
of the Company, as amended July 10, 2015
|
|
3/30/2016
|
10-K
|
3.ii.
|
|
4.1(a)
|
Specimen
Common Stock Certificate
|
|
8/8/1996
|
SB-2
|
4.1
|
4.1(b)
|
Form of
Underwriter's Warrant
|
|
8/8/1996
|
SB-2
|
4.2
|
2008
Stock Incentive Plan dated May 20, 2008
|
|
5/22/2008
|
S-8
|
10.1(11)
|
|
2018
Employee Stock Option Plan
|
|
4/16/2019
|
10-K
|
10.72
|
2018
Officer, Directors, Employees and Consultants Nonqualified Stock
Option Plan
|
|
4/16/2019
|
10-K
|
10.73
|
|
2018
Stock Option Agreement – Nonqualified Stock
Option
|
|
4/16/2019
|
10-K
|
10.74
|
|
2018
Stock Option Agreement – Employee Plan
|
|
4/16/2019
|
10-K
|
10.75
|
|
Employment
Agreement between Company and Stephen T. Chen, Ph.D. dated 12/31/20
and effective 01/01/21
|
X
|
3/30/2021
|
10-K
|
10.1(f)
|
|
Amendment
No. 1 to Employment Agreement between Company and Stephen T. Chen,
Ph.D. effective 01/01/21
|
X
|
3/30/2021
|
10-K
|
10.1(g)
|
|
Employment
Agreement between Company and Bernard Cohen dated 12/31/20 and
effective 01/01/21
|
X
|
3/30/2021
|
10-K
|
10.1(h)
|
|
Settlement
Agreement and Mutual General Release, effective
12/24/20
|
X
|
3/30/2021
|
10-K
|
10.1(i)
|
|
Extension
of the consulting agreement and pre-existing warrant certificate
between the Company and i2China Management Group, LLC (originally
dated April 15, 2018), dated November 30, 2020
|
X
|
3/30/2021
|
10-K
|
10.1(j)
|
|
Securities
Purchase Agreement between Company and Ainos, Inc., dated December
24, 2020
|
|
12/30/2020
|
8-K
|
2.1
|
|
14.1
|
Code of
Ethics
|
|
|
|
|
Certification
of Chief Executive Officer (Principal Executive Officer) required
by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act
of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
|
X
|
3/30/2021
|
10-K
|
31.1
|
|
906
Certification
|
X
|
|
|
|
|
101.INS
|
XBRL
Instance Document – the instance document does not appear in
the Interactive Data File because XBRL tags are embedded within the
XBRL document.
|
X
|
|
|
|
101.SCH
|
XBRL
Taxonomy Extension Schema Document
|
X
|
|
|
|
101.CAL
|
XBRL
Taxonomy Extension Calculation Linkbase
|
X
|
|
|
|
101.DEF
|
XBRL
Taxonomy Extension Definition Linkbase
|
X
|
|
|
|
101.LAB
|
XBRL
Taxonomy Extension Label Linkbase
|
X
|
|
|
|
101.PRE
|
XBRL
Taxonomy Extension Presentation Linkbase
|
X
|
|
|
|
104.1
|
Cover Page Interactive Data File
|
X
|
|
|
|
|
AMARILLO
BIOSCIENCES, INC.
|
|
|
|
|
|
|
Date: March 30,
2021
|
By:
|
/s/ Stephen Chen
|
|
|
|
Stephen Chen,
Chairman of the Board,
|
|
|
|
Chief Executive
Officer and Chief Financial Officer
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Stephen Chen
|
|
Chairman of the
Board,
|
|
March
30, 2021
|
Stephen
Chen
|
|
Director
Chief
Executive Officer
and
Chief Financial Officer
|
|
|
|
|
|
|
|
/s/ Yasushi Chikagami
|
|
Director
|
|
March
30, 2021
|
Yasushi
Chikagami
|
|
|
|
|
|
|
|
|
|
/s/ Daniel Fisher
|
|
Director
|
|
March
30, 2021
|
Daniel
Fisher
|
|
|
|
|
|
|
|
|
|
/s/ Nicholas Moren
|
|
Director
|
|
March
30, 2021
|
Nicholas
Moren
|
|
|
|
|
|
|
|
|
|
/s/ Beatrice Liu
|
|
Director
|
|
March
30, 2021
|
Beatrice
Liu
|
|
|
|
|
Contents
|
Report
of Independent Registered Public Accounting Firm
|
F-1
|
|
|
Balance
Sheets
|
F-2
|
|
|
Statements
of Operations
|
F-3
|
|
|
Statements
of Stockholders’ Equity (Deficit)
|
F-4
|
|
|
Statements
of Cash Flows
|
F-5
|
|
|
Notes
to Financial Statements
|
F-6
|
|
|
/s/PWR
CPA, LLP
|
|
|
|
We
have served as the Company’s auditor since 2020.
|
|
|
|
Houston,
Texas
|
|
|
|
March
30, 2021
|
|
|
December
31,
2020
|
December
31,
2019
|
Assets
|
|
|
Current
assets:
|
|
|
Cash
and cash equivalents
|
$22,245
|
$409,039
|
Inventory
|
3,024
|
4,131
|
Prepaid
expense and other current assets
|
51,144
|
32,124
|
Total current
assets
|
76,413
|
445,294
|
Patents,
net
|
180,628
|
146,263
|
Property and
equipment, net
|
3,249
|
5,069
|
Total
assets
|
$260,290
|
$596,626
|
|
|
|
Liabilities
and Stockholders’ Equity (Deficit)
|
|
|
Current
liabilities:
|
|
|
Accounts
payable and accrued expenses
|
$145,567
|
$208,727
|
Advances
from investors
|
-
|
100,000
|
Convertible
notes payable
|
953,001
|
444,581
|
Total current
liabilities
|
1,098,568
|
753,308
|
Total
liabilities
|
1,098,568
|
753,308
|
|
|
|
Commitments and
contingencies
|
|
|
|
|
|
Stockholders’
equity (deficit)
|
|
|
Preferred
stock, $0.01 par value:
|
|
|
Authorized
shares – 10,000,000,
|
|
|
Issued and
outstanding shares – 0 at December 31, 2020 and December 31,
2019, respectively
|
-
|
-
|
Common
stock, $0.01 par value:
|
|
|
Authorized
shares – 100,000,000,
|
|
|
Issued and
outstanding shares –42,066,172 and 40,516,351 at December 31,
2020 and 2019, respectively
|
420,662
|
405,164
|
Additional
paid-in capital
|
4,961,315
|
4,207,786
|
Accumulated
deficit
|
(6,220,255)
|
(4,769,632)
|
Total
stockholders’ equity (deficit)
|
( 838,278)
|
(156,682)
|
Total liabilities
and stockholders’ equity (deficit)
|
$260,290
|
$596,626
|
|
Years
ended
December
31,
|
|
|
2020
|
2019
|
Revenues
|
$16,563
|
$11,731
|
Cost of
revenues
|
(11,277)
|
(8,772)
|
Gross
margin
|
5,286
|
2,959
|
|
|
|
Operating
expenses:
|
|
|
Research
and development expenses
|
389
|
52,510
|
Selling,
general and administrative expenses
|
1,445,332
|
1,530,862
|
Total
operating expenses
|
1,445,721
|
1,583,372
|
|
|
|
Operating
loss
|
(1,440,435)
|
(1,580,413)
|
|
|
|
Other income
(expense):
|
|
|
Interest
expense, net
|
(10,188)
|
(885)
|
Net
loss
|
$(1,450,623)
|
$(1,581,298)
|
|
|
|
Basic and diluted
net loss per average share available to common
shareholders
|
$(.04)
|
$(0.04)
|
|
|
|
Weighted average
common shares outstanding – basic and diluted
|
40,730,934
|
39,896,388
|
|
Preferred
Stock
|
Common
Stock
|
Additional Paid
in
|
Accumulated
|
Total
Stockholders'
|
||
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Equity
|
Balance at December 31,
2018
|
-
|
$-
|
39,117,524
|
$391,175
|
3,527,238
|
(3,188,334)
|
730,079
|
Issuance of stock for
compensation
|
-
|
-
|
231,675
|
2,317
|
67,183
|
-
|
69,500
|
Issuance of common stock for
cash
|
-
|
-
|
615,000
|
6,150
|
123,850
|
-
|
130,000
|
Issuance of stock for
debt
|
-
|
-
|
552.152
|
5,522
|
94,478
|
-
|
100,000
|
Warrant expense
|
-
|
-
|
-
|
-
|
37,984
|
-
|
37,984
|
Option expense
|
-
|
-
|
-
|
-
|
357,053
|
-
|
357,053
|
Net Loss
|
-
|
-
|
-
|
-
|
-
|
(1,581,298)
|
(1,581,298)
|
Balance at December 31,
2019
|
-
|
$-
|
40,516,351
|
$405,164
|
4,207,786
|
(4,769,632)
|
(156,682)
|
Issuance of stock for
compensation
|
-
|
-
|
1,149,821
|
11,498
|
283,192
|
-
|
294,690
|
Issuance of stock for
subscriptions
|
-
|
-
|
400,000
|
4,000
|
96,000
|
-
|
100,000
|
Warrant expense
|
-
|
-
|
-
|
-
|
11,585
|
-
|
11,585
|
Option expense
|
-
|
-
|
-
|
-
|
362,752
|
-
|
362,752
|
Net loss
|
-
|
-
|
-
|
-
|
-
|
(1,450,623)
|
(1,450,623)
|
Balance at December 31,
2020
|
-
|
$-
|
42,066,172
|
$420,662
|
4,961,315
|
(6,220,255)
|
(838,278)
|
|
Year
Ended
December
31,
2020
|
Year
Ended
December
31,
2019
|
Cash flows from
Operating Activities
|
|
|
Net
loss
|
$(1,450,623)
|
$(1,581,298)
|
Adjustments to
reconcile net loss to net cash used in operating
activities:
|
|
|
Depreciation
and amortization
|
14,698
|
22,241
|
Stock
issued for compensation
|
150,440
|
|
Warrant
expense
|
11,585
|
37,984
|
Option
expense
|
362,752
|
357,053
|
Changes in
operating assets and liabilities:
|
|
|
Inventory
|
1,107
|
(4,131)
|
Prepaid expense and
other current assets
|
(19,020)
|
(5,544)
|
Accounts
payable and accrued expenses
|
419,618
|
261,674
|
Accrued
interest – related party
|
9,892
|
2,545
|
Net cash used in
operating activities
|
(499,551)
|
(909,476)
|
Cash flows from
Investing Activities
|
|
|
Investment in
patents
|
(7,243)
|
(11,469)
|
Capital
expenditures
|
-
|
(1,638)
|
Net cash used in
investing activities
|
(7,243)
|
(13,107)
|
Cash flows from
Financing Activities
|
|
|
Proceeds
from private placement offering, net
|
-
|
125,048
|
Proceeds from
convertible note payable – related party
|
120,000
|
-
|
Repayment on
convertible note payable – related party
|
-
|
(70,080)
|
Net cash provided
by financing activities
|
120,000
|
54,968
|
Net change in
cash
|
(386,794)
|
(867,615)
|
Cash and cash
equivalents at beginning of period
|
409,039
|
1,276,654
|
Cash and cash
equivalents at end of period
|
$22,245
|
$409,039
|
Supplemental Cash
Flow Information
|
|
|
Cash
paid for interest
|
$855
|
$903
|
Non-Cash
Transactions
|
|
|
Stock issued for
accrued liabilities
|
104,250
|
$69,500
|
Stock issued for
subscription
|
$100,000
|
$-
|
Conversion of debt
to common stock
|
$-
|
$100,000
|
Stock issued for
patent costs
|
$40,000
|
$
|
Stock issued for
advances from investors
|
$-
|
$100,635
|
|
2020
|
2019
|
Furniture and
equipment
|
$94,625
|
$94,625
|
Automobiles
|
4,912
|
4,912
|
Software
|
8,012
|
8,012
|
|
107,549
|
107,549
|
Less: accumulated
depreciation
|
(104,300)
|
(102,480)
|
Property, equipment
and software, net
|
$3,249
|
$5,069
|
|
2020
|
2019
|
Patents
|
$245,898
|
$198,655
|
Less: accumulated
amortization
|
(65,270)
|
(52,392)
|
Patents,
net
|
$180,628
|
$146,263
|
2020
|
12,435
|
2021
|
11,222
|
2022
|
10,818
|
2023
|
10,818
|
2024
|
10,818
|
Thereafter
|
124,517
|
Total
expense
|
$180,628
|
Stock Plans
1
|
|
Issue Date
Range
|
Total Shares
Authorized
|
Shares
Issued
|
Shares
Remaining
|
Amarillo
Biosciences, Inc., 2018 Employee Stock Option Plan,
2
|
|
9/26/18 –
9/26/28
|
6,000,000
|
850,000
|
5,150,000
|
Amarillo
Biosciences, Inc., 2018 Officers, Directors, Employees, and
Consultants Nonqualified Stock Option Plan
|
|
9/26/18 –
9/26/28
|
20,000,000
|
3,807,000
|
16,193,000
|
Date
|
Number of
Options 1Qualified*
|
Number of
Options Nonqualified
|
Weighted Average
Exercise Price
|
Weighted Average
Remaining Contractual Term
|
Aggregate
Intrinsic Value
|
Balance December
31, 2018
|
950,000
|
3,995,000
|
$0.38
|
9
years -
|
-
|
Exercised
|
-
|
-
|
-
|
-
|
-
|
Expired or
Forfeited
|
100,000
|
188,000
|
$0.38
|
-
|
-
|
Balance December
31, 2019
|
850,000
|
3,807,000
|
$0.38
|
8
years -
|
-
|
Granted
2020
|
-
|
-
|
-
|
-
|
|
Exercised
|
-
|
-
|
-
|
-
|
-
|
Expired or
Forfeited
|
|
|
$0.38
|
-
|
-
|
Balance December
31, 2020
|
850,000
|
3,807,000
|
$0.38
|
7
years -
|
|
Vested as of
December 31, 2020
|
390,000
|
1,522,800
|
$0.38
|
7
years -
|
|
|
December
31,
2020
|
December
31,
2019
|
Provision (benefit)
at statutory rate
|
$(305,000)
|
$(332,000)
|
Permanent
differences
|
80,000
|
85,000
|
Change in valuation
allowance
|
225,000
|
247,000
|
|
$-
|
$-
|
|
December
31,
2020
|
December
31,
2019
|
Deferred tax
assets:
|
|
|
Net
operating loss carryforward
|
$3,725,000
|
$5,239,000
|
Deferred
tax assets
|
3,725,000
|
5,239,000
|
|
|
|
Deferred tax
liabilities:
|
-
|
-
|
Net deferred tax
assets
|
3,725,000
|
5,239,000
|
Valuation
allowance
|
(3,725,000)
|
(5,239,000)
|
|
$-
|
$-
|
|
Amarillo Biosciences, Inc.
|
|
|
EMPLOYEE:
|
|
By:
|
/s/ John Junyong Lee
|
|
By:
|
/s/
Stephen T. Chen
|
|
|
John Junyong
Lee
|
|
|
Dr. Stephen T. Chen, Ph.D. |
|
|
Secretary
|
|
|
|
|
|
|
|
|
|
|
Date:
|
12/31/2020
|
|
Date:
|
12/31/2020
|
|
|
Amarillo Biosciences, Inc.
|
|
|
EMPLOYEE:
|
|
By:
|
/s/ John Junyong Lee
|
|
By:
|
/s/
Stephen T. Chen
|
|
|
John Junyong
Lee
|
|
|
Dr. Stephen T. Chen, Ph.D. |
|
|
Secretary
|
|
|
|
|
|
|
|
|
|
|
Date:
|
January 19, 2021 |
|
Date:
|
January 19, 2021 |
|
|
Amarillo Biosciences, Inc.
|
|
|
EMPLOYEE:
|
|
By:
|
/s/ John Junyong Lee
|
|
By:
|
/s/ Bernard
Cohen
|
|
|
John Junyong Lee |
|
|
Bernard Cohen |
|
|
Secretary |
|
|
|
|
|
|
|
|
|
|
Date:
|
12/31/2020 |
|
Date:
|
12/31/2020
|
|
|
By:
|
/s/
Bernard Cohen
|
|
|
|
Bernard Cohen |
|
|
|
|
|
|
AMARILLO
BIOSCIENCES, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ John Junyong Lee
|
|
|
|
John Junyong Lee |
|
|
|
Secretary |
|
|
AMARILLO
BIOSCIENCES, INC, a Texas Corporation
|
|
|
|
|
|
|
|
By:
|
/s/ Stephen T.
Chen
|
|
|
|
Dr. Stephen T. Chen |
|
|
|
Chairman & CEO |
|
|
i2CHINA MANAGEMENT
GROUP, LLC (“CONSULTANT”)
|
|
|
|
|
|
|
|
By:
|
/s/ Lawrence K.
Lin
|
|
|
|
Lawrence K. Lin |
|
|
|
Manager |
|
Date: March 30, 2021
|
|
/s/ Stephen T.
Chen
|
|
|
Stephen T. Chen, Chairman of the Board,
Chief Executive Officer and Chief Financial Officer
|
Date: March 30, 2021
|
|
/s/ Stephen T.
Chen
|
|
|
Stephen T. Chen, Chairman of the Board,
Chief Executive Officer and Chief Financial Officer
|
Date: March 30, 2021
|
|
/s/ Stephen T.
Chen
|
|
|
Stephen T. Chen, Chairman of the Board,
Chief Executive Officer and Chief Financial Officer
|